莫伐倍林：三螺旋之舞 Muvalaplin-Dancing of the Triple Helix

凌凯科技

2024-11-29

Born with a bad seed

Lp(a) is similar to LDL cholesterol, sometimes called 'bad cholesterol’,but is more sticky, increasing risk of blockages and blood clots in arteries.Common LDL lowering drugs such as statins don't have the same lowering effect on Lp(a). Being largely genetic,Lp(a) is also difficult to control through diet, exercise and other lifestyle changes. Although Lp(a) was discovered nearly 60 years ago there still aren't any widely accessible treatments available to lower levels and reduce cardiovascular risk. The researcher says that this drug is a gamechanger in more ways than one. It can be delivered in an oral table. Lp(a) is essentially a silent killer with no available treatment, this drug changes that. This drug may also have potential to be used in the treatment of other vascular and valve disease.

A silver lining

A new drug offers a breakthrough world first treatment for Lipoprotein(a), a largely genetic form of cholesterol that increases the risk of heart attack and stroke. High levels of Lipoprotein(a), known as Lp(a), impact one in five people globally with no approved treatment currently on the market. The trial demonstrated the success of Muvalaplin - the first oral drug ever developed to target Lp(a)- effectively lowering levels by up to 65%. It works by disrupting the ability for Lp(a) to form in the body. Monash University researchers published their research results in the journal JAMA¹.

Graceful triple helix

Crystal structure analysis of the interactions between Muvalaplin and KIV8 shows that the trimeric molecule is capable of binding to three KIV8 domains simultaneously, which suggests that multi-KIV domain interactions are possible in apo(a) . Muvalaplin-HCl salt binds to KIV8 selectively with a potency of 22 nM and inhibits the formation of Lp(a) particles in vitro with an IC50 value of 0.09 nM (n = 9). In the Lp(a) transgenic mouse model, the plasma levels of LY3473329-HCl salt increased in a dose-dependent manner, and treatment with Muvalaplin-HCl reduced the levels of Lp(a) with an absolute ED50 of 3 mg kg−1, with a maximum Lp(a) reduction of 92% after five days of BID oral dosing. In cynomolgus monkeys, Muvalaplin reduced median Lp(a) levels in a dose-dependent manner by up to 71% in the 100 mg kg−1 once daily (QD) cohort, compared with baseline. Multivalency, which allowed the engagement of multiple apo(a) KIV domains, considerably increased the potency and efficacy of inhibitors of Lp(a) formation in both in vitro and in vivo models of Lp(a) reduction, as compared with monovalency.²

Latest progress

The newest Eli Lilly and Company recently announced positive results in a Phase 2 clinical trial for Muvalaplin showed that the trial met its primary endpoint, and Muvalaplin was able to significantly reduce Lp (a) levels in adult patients, showing significant improvement in the percentage change in Lp (a) levels from baseline to week 12. At the 12-week primary endpoint, Muvalaplin (10 mg, 60 mg and 240 mg) showed significant reductions in Lp(a) levels compared to placebo. The placebo-adjusted reductions were up to 85.8% using an intact Lp(a) assay and up to 70.0% using an apo(a) assay. Specifically, the reductions were 47.6% (10 mg), 81.7% (60 mg) and 85.8% (240 mg) with the intact Lp(a) assay, and 40.4% (10 mg), 70.0% (60 mg) and 68.9% (240 mg) with the apo(a) assay.

LinkChem Lp(a) buildingblock series

Reference：

1. Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, et al. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. JAMA. 2023;330(11):1042–53

2. Nuria D, Carlos P, Ana ME, Gema S, Julian P, Laura FM , et al. Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. Nature. 2024;629:945–950

This article is published by LinkChem Technology Co., Ltd. Welcome to scan the QR code to follow us and explore the mysteries of chemistry together.

凌凯科技旗下全球数字化医药科研服务平台

Chemenu是LinkChem旗下全球数字化医药科研服务平台，深耕药物分子砌块的设计与研发，旨在赋能早期科学研究，加速药物发现。公司拥有数量庞大、品类多样的高品质、高性价比的分子砌块，并具备优秀的合成化学能力，可为国内外化学和药物研发领域用户提供高质量的有机分子化合物，助力医药研发。

● 我们的优势 ●

研产无缝衔接

降风险、保品质、提收率

8,600m²+研发运营中心

2大自有生产基地

严格的IP保护体系

完善的 AI、POI技术平台

● 专注领域 ●

Chemically Inspired Dreams

Accelerate Drug Discovery

上海凌凯科技股份有限公司

LinkChem Technology Co., Ltd.

— 上海总部研发中心 —

凌凯科技·LinkChem成立于2011年，是一家专注于有机合成化学、流体工程技术应用的研发型产业化高新技术企业，主要提供小分子化合物研发、生产及商业化解决方案。公司业务横跨且深耕医药、新材料、新能源三大领域，以创新驱动、工程工艺协同，实现对客户多元化需求的快速响应、加速产品服务落地、帮助客户提升整体经济效益。

历经13年发展，凌凯科技有着深厚的研发实力和产业转化能力。公司拥有超8,600㎡研发运营中心，依托经验丰富、实力强劲的核心研发团队，搭建一站式生物医药 CDMO平台；坚持实施科技创新驱动战略，自主研发 “流动化学与微通道”、“绿色催化”两大核心技术平台，推进工艺创新与产业升级；公司旗下两座商业化生产工厂，建造了业内一流车间，聚力发展新质生产力，实现生产规模化、智能化与高效化。
通过持续和深入的商业化布局，公司业务已覆盖全球五大洲，与5,000多家制药企业和研发机构建立了良好合作关系。凌凯科技始终以市场需求为导向，秉承“科学、严谨、创新、合作”的发展理念，立足中国，辐射全球，致力于成为全球客户值得信赖的医药、新材料与新能源领域重要合作伙伴，不断为生命健康和绿色能源革新事业贡献力量。

上海凌富药物研究有限公司

Linkfull Laboratories Co., Ltd.

— 原料药研发及生产 —

上海凌凯科技旗下的控股子公司：上海凌富药物研究有限公司，是由上海凌凯科技股份有限公司与江西富祥药业股份有限公司联合发起并成立。新成立的合资公司凭借上海凌凯科技多年来积累的丰富研发经验和市场终端客户资源，以及江西富祥药业国际质量监管理念接轨的GMP管理体系、科学完善的EHS管理体系，进一步深耕CDMO全球国际业务。合资公司凭借上海的地域优势、信息优势和人才优势，积极扩充研发人员，建设专业人才队伍，提高企业的研发创新服务能力，稳步推进创新药从临床前研究到商业化生产的一体化综合服务能力，增强企业的整体竞争力。

上海旭流化学科技有限公司

Shanghai XFlow Chemical Technology Co., Ltd.

— 新催化剂应用研究及流动化学技术开发 —

上海旭流化学科技有限公司是一家专业做新催化剂应用研究和流动化学技术开发的公司。公司位于上海市浦东新区康新公路3399号5号楼，在上海拥有1600平方米的研发实验室，拥有员工35名，实验室内拥有CSTR、PFR、微通道反应器、连续空气氧化反应器、连续格式反应器、固定床、滴流床反应器，连续光反应器等等各种流动化学的反应器装置。在江西的5000平方米的中试车间也正在建设之中。公司有工艺开发/反应器设计/工艺模拟/工程设计/工艺安全/分析支持等部门。

公司在反应的连续化工艺开发中有一定的经验，并已实施了多个产品的多步连续工艺，帮助客户实现了传统间歇反应釜工艺向连续流技术的升级和改造，也帮助客户开发出新催化剂的工艺，取得了非常好的社会效应和经济效应。

江西亚太科技发展有限公司

Jiangxi Yatai Technology Co., Ltd.

— 中试研究与商业化生产 —

2018年下半年，上海凌凯科技全资收购江西亚太科技，一家高端医药中间体生产工厂。目前江西亚太工厂一、二期改造均已完成，工厂采用国际先进的EHS管理体系，目前已完全具备完善的研发，中控与商业化生产能力。江西亚太科技已于2020年通过跨国知名制药集团如AMGEN,SANOFI等全球知名药企的现场审计。2021年上半年，江西亚太科技自主新建的7000平米研发中心完成装修并全面投入使用，该研发中心集研发、中试、分析和行政办公于一体，并配备高端的连续流技术专用实验室，可同时容纳60-80个新药分子砌块项目的试验开展工作。